Ryan Scott

A real-world study showed zanubrutinib was linked with fewer cardiac adverse effects vs ibrutinib and acalabrutinib in chronic lymphocytic leukemia.

Anne Favret, MD discusses the evolution of treatment with endocrine-based combination therapies in HR-positive/HER2-negative metastatic breast cancer.

Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.

The FDA has accepted for review the new drug application for SH-201 for the treatment of patients with certain forms of leukemia and other cancers.

The FDA has granted breakthrough therapy designation to sunvozertinib for patients with locally advanced or metastatic NSCLC with an EGFR exon 20 insertion mutation.

Adjuvant treatment with the personalized neoantigen vaccine, autogene cevumeran, delayed pancreatic cancer recurrence in pancreatic ductal adenocarcinoma.

Eduardo M. Sotomayor, MD, discusses updates in the treatment of hematologic malignancies, highlighting research on antibody-drug conjugate and bispecific antibody combinations.

RNX-051 displays impact on bacterial biomass in patients with right-sided colorectal cancer and right-sided colon polyps/adenomas.

Eduardo M. Sotomayor, MD, expands on the evolving treatment paradigm for hematologic malignancies, highlighting treatment with CAR T-cell therapy.

Bernard H. Bochner, MD, FACS, discusses updates in the treatment of muscle-invasive bladder cancer and ongoing trials in the space.

Positive phase 2 findings for CAN-2409 plus valacyclovir in pancreatic ductal adenocarcinoma have been reported.

Carlos L. Arteaga, MD, discusses the utility of vepdegestrant alone or in combination in patients with ER-positive, HER2-negative advanced breast cancer.

Daniel P. Petrylak, MD, discusses the importance of molecularly-driven clinical trials and ongoing research with novel therapeutics in urothelial carcinoma.

Bernard H. Bochner, MD, FACS, highlights advancements in early-stage muscle-invasive bladder cancer and the necessity for multimodality approaches.

Wenxin (Vincent) Xu, MD, shares recent updates in the treatment of renal cell carcinoma, including insights into ongoing research and trials within the space.

Daniel P. Petrylak, MD, discusses advancements in the treatment of patients with bladder cancer.

Wenxin (Vincent) Xu, MD, discusses the evolving landscape of systemic therapy in RCC, sharing how he makes treatment decisions amid the changing treatment space.

TTFields plus supportive care improved time to intracranial progression in patients with brain metastases from non–small cell lung cancer.

Investigators emphasize the importance of firming a widely understood definition of unmet needs in cancer care due to their impact on drug approvals.

Pierre Gholam, MD, discusses primary considerations for the first-line treatment of patients with advanced, unresectable HCC.

Anlotinib plus etoposide, carboplatin, and placebo improved PFS vs etoposide plus carboplatin and 2 placebos in first-line ES-SCLC.

The EMA’s CHMP has recommended the approval of enzalutamide with or without androgen deprivation therapy in biochemically recurrent nmHSPC.

Avutometinib plus defactinib led to tumor regression in most heavily pretreated patients with recurrent low-grade serous ovarian cancer.

Francine Brinkhuis, MSc, and Lourens T. Bloem, PharmD, MSc, highlight findings from an analysis of the benefit and revenue for EU-approved oncology drugs.

Brentuximab vedotin/lenalidomide/rituximab led to an OS improvement vs lenalidomide/rituximab/placebo in relapsed/refractory diffuse large B-cell lymphoma.

Neel P. Chudgar, MD, discusses the nuances of defining resectability in patients with non–small cell lung cancer.

Eirwen M. Miller, MD, discusses her experience in the oncology field and the importance of ensuring gender is not a defining quality for oncologists.

Suzanne B. Coopey, MD, highlights the initial challenges that she experienced during her residency and expands on the support found in the field.

The EMA has received a type II variation application for an indication extension of D-VRd for the treatment newly diagnosed multiple myeloma.

China’s National Medical Products Administration has accepted the second NDA for first-line taletrectinib for ROS1-positive non–small cell lung cancer.